Vice President of Emerging Technology & Innovation, Eli Lilly
Dr. Angèle Maki is a business development executive with over sixteen years of deal-making experience spanning small biotech and big pharma. She is currently a Vice President of Emerging Technology & Innovation at Eli Lilly and Company where she leads search & evaluation efforts in the Bay Area for Lilly Research Labs. At Lilly she also plays key roles with Lilly Gateway Labs, Lilly’s new incubator-like facility in SSF, and with Lilly New Ventures, Lilly’s corporate VC group.
Prior to Lilly, Angèle held business development roles with increasing responsibility starting at Medarex followed by BMS (which acquired Medarex), Genentech, 23andMe, and Merck & Co. During her career, she has successfully led diligence and negotiations on numerous in- and out-licensing transactions, from early-stage research technologies to clinical-stage assets.
Angèle has a Ph.D. in biological chemistry from Stanford University and completed postdoctoral work in molecular biology at The Scripps Research Institute in La Jolla. She completed her B.Sc. in chemistry at the University of Winnipeg in Canada.